Navigation Links
EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011

LONDON, June 24, 2011 /PRNewswire/ --


EP Vantage, part of EvaluatePharma, was presented with the coveted Commentator of the Year Award at the European Mediscience Awards, sponsored by Matrix, on June 22, 2011.

The award, which honours clear and concise commentary in the pharma and biotech sector, can be given to analysts, journalists, columnists, research houses or specialist websites dedicated to providing sharp, perceptive and penetrating commentary.

The EP Vantage team - Lisa Urquhart, Amy Brown, Christian Glennie and Jonathan Gardner - beat a strong field that included analysts and fellow journalists to claim the prize.

Speaking about the achievement Jonathan de Pass, chief executive of EvaluatePharma, said: "I'm thrilled that the EP Vantage team have won the European Mediscience 2011 Commentator of the Year award.

The life-science industry is well served for commentary by several long-established publications and by many securities analysts so this is all the more an incredible achievement given that EP Vantage has been going for less than four years. After twice being runners-up for this award, this is well-deserved recognition for the team."

Notes for Editors:

About EP Vantage

Launched in 2007 by EvaluatePharma, EP Vantage is a daily online comment and analysis service providing insightful, forward-looking financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A in the biotech and pharma industry.

Written by an experienced team of journalists, EP Vantage prides itself on covering market catalysts weeks and even months ahead of other industry sources.

EP Vantage's analysis is powered by EvaluatePharma, the leaders in consensus forecasts in the pharmaceutical industry for over 12 years.

EP Vantage editorial team

Lisa Urquhart, Editor

A financial journalist for over 11 years, Lisa joined EP Vantage in 2007 as editor. Prior to this she spent seven years at the Financial Times working in a variety of roles including Biotechnology Correspondent. During her time at the FT Lisa generated a number of exclusives, including Barr's $2.2bn takeover of Pliva. Lisa has overseen the successful launch of EP Vantage and guided its strategic development to create an award-winning comment and analysis service.  Nominated for the third consecutive year, EP Vantage received the European MediScience Awards Commentator of the Year award in 2011.

Amy Brown, Senior Reporter

Amy joined EP Vantage from Thomson Financial News, where she covered the European pharmaceutical and biotechnology sectors for several years. She has extensive experience working as a financial journalist, working for companies including Bloomberg News, and has been a contributor to publications such as Corporate Financier. Amy's keen sense for news, highly analytical mind and writing ability have all contributed to the growing recognition and respect EP Vantage has commanded.

Christian Glennie, Senior Editorial Analyst

Christian joined EP Vantage from EvaluatePharma, where he worked as an analyst for seven years, developing extensive and in-depth knowledge of the pharmaceutical industry. Previously responsible for generating forecast models for over 60 pharma and biotech companies, Christian provides analysis and insight for EP Vantage content and is also an invaluable part of the writing team.

Jonathan Gardner, Reporter

Jonathan was previously a freelance journalist on a number of healthcare titles including Elsevier Global Medical News. Prior to this he was communications manager at US publication Health Affairs Journal and bureau chief for Modern Healthcare magazine. Jonathan brings a wealth of experience in both the US primary healthcare market and regulatory affairs to EP Vantage, extending the reach of the publication.

About the European Mediscience Awards

The European Mediscience Awards Dinner, sponsored by Matrix, is the largest annual gathering of quoted biotech and life sciences companies in Europe.  It celebrates the best in the sector and highlights the achievements of individuals and companies.  The event recognises the importance of access to the capital markets to fund growth and innovation and is attended by specialist investors, advisors, media and analysts.  

Now it is 10th year, the winners were announced at a dinner which was held at the Hotel Intercontinental, London W1 on Wednesday 22 June 2011.


Lisa Urquhart
EP Vantage Editor

T: +44(0)20-7539-1819
EP Vantage
11-29 Fashion Street
E1 6PX
United Kingdom

Andrew Beaven
Marketing Director, EvaluatePharma Ltd

T: +44(0)20-7539-1818
EvaluatePharma Ltd
11-29 Fashion Street
E1 6PX
United Kingdom

SOURCE EvaluatePharma Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
4. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
5. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
6. St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors
7. Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs
8. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
9. Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma
10. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
11. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... Antonio, TX (PRWEB) , ... November 26, 2015 , ... ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction ... , “We wake up every day excited to rebuild lives and it’s an honor ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/26/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class Asterisk based contact ... and reliability. , The new Q-Suite 6 platform is based on the latest Java ... into a specific piece of software for many key components of the suite. Much ...
Breaking Medicine News(10 mins):